ஆக்ற் News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from ஆக்ற். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In ஆக்ற் Today - Breaking & Trending Today
(0) - Inhibition of hyperactive RAS network signaling is nine times more effective with gedatolisib than with a PI3K-α inhibitor - - Synergistic cooperation between PI3K/mTOR and BCL signaling detected, suggesting potential patient benefit of combining gedatolisib with a BCL inhibitor - MINNEAPOLIS, MN / ACCESSWIRE / April 12, 2021 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated companion diagnostic (CDx) and therapeutic strategy for treating patients with cancer, presented results of studies evaluating gedatolisib (a pan-PI3K/mTOR inhibitor), inavolisib (a PI3K- α inhibitor), and navitoclax (a BCL inhibitor) in breast and ovarian patient tumors. Results were presented in two e-posters at the American Association for Cancer Research (AACR) Annual Meeting. ....
(1) ITM AG today announced that the company will present a poster describing the clinical trial design for its ongoing phase III trial COMPETE for their lead candidate, no-carrier-added Lutetium-177-Edotreotide (n.c.a. 177Lu-Edotreotide), a Targeted Radionuclide Therapy for gastroenteropancreatic neuroendocrine tumors (GEP-NETs), at the upcoming American Association of Cancer Research (AACR) Virtual Annual Meeting on April 10-15, 2021 and May 17-21, 2021. The e-poster website will be launched on Saturday, April 10, 2021 at 8.30am ET and will remain available for viewing until Monday, June 21, 2021. Please see below for details on the poster abstract. Session Category: Phase III Clinical Trials in Progress Title: COMPETE Phase III Trial Peptide Receptor Radionuclide Therapy (PRRT) with ....
OSE Immunotherapeutics to Present New Data Reflecting Expansion and Progress on its Immuno-Oncology and Inflammation Preclinical Portfolio at the 2021 AACR Annual Meeting Permanent Abstract Number: 1636 Title: Optimized antagonist anti-PD-1/IL-7 mutein bispecific antibody to sustain exhausted T cell function and to disarm Treg suppressive activity. Morello A., Seité M., Durand J, Thépenier V., Teppaz G., Pengam S., Wilhelm E., Desselle A., Girault I., Mary C., Poirier N. Session Type: E-Poster Session Session Title: Therapeutic Antibodies Title: Triggering the resolution of inflammation with agonistic anti-ChemR23 antibody dampens inflammation-driven carcinogenesis Gauttier V., Lavy M., Trilleaud C., Biteau K., Girault I., Belarif L., Teppaz G., Mary C., Thepenier V., Blanquart C., Barillé-Nion S., Poirier N. ....
Mitazalimab synergizes with chemotherapy - Alligator Bioscience presents new preclinical data at AACR Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that an abstract for a poster presentation at the AACR (American Association for Cancer Research) Annual Meeting 2021, presenting new preclinical data for the clinical asset mitazalimab, is now released. The AACR Annual Meeting 2021 will be held in a virtual format over two one-week periods in April and May 2021. Alligator Bioscience s abstract will be presented in an ePoster session during April 10-15. Alligator Bioscience has previously shown that mitazalimab synergizes effectively with immune checkpoint inhibitors and vaccines. The abstract, titled Mitazalimab, a potent CD40 agonist with potential for combination with chemotherapy , demonstrates that mitazalimab synergizes with chemotherapy, notably FOLFIRINOX, leading to improved long-term survival in a preclinical tumor model. ....
Curis Announces Abstract for CA-4948 Accepted for Presentation at the American Association for Cancer Research Annual Meeting yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.